Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
06/2005
06/30/2005WO2005058930A2 Methods for production of recombinant vascular endothelial cell growth inhibitor
06/30/2005WO2005058865A2 Assay for entactogens
06/30/2005WO2005058815A2 Ip-10 antibodies and their uses
06/30/2005WO2005058369A2 Compositions of l-caldesmon for treating viral infection
06/30/2005WO2005058361A1 USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD
06/30/2005WO2005058358A2 Use of agents derived from ceacam1 for the treatment of inflammatory diseases
06/30/2005WO2005058357A1 Virus-like particle (vlp) as vaccine
06/30/2005WO2005058354A1 Recombinant vibrio cholerae strain and vaccine comprising said strain
06/30/2005WO2005058353A1 Passive immunization against clostridium difficile disease
06/30/2005WO2005058350A1 Novel vaccines for treating or preventing infections by echinococus parasites
06/30/2005WO2005058344A1 Antimicrobial composition
06/30/2005WO2005058342A1 Methods and compositions for modulating ovulation
06/30/2005WO2005058323A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 1 (mGLuR1) ANTAGONISTS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS)
06/30/2005WO2005058322A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 1 (mGLuR1) ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
06/30/2005WO2005058321A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 5 (mGLuR5) ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS.
06/30/2005WO2005058229A2 Antiviral proteins with improved properties and methods therefor
06/30/2005WO2005058058A1 Frozen confectionery product comprising ice structuring proteins
06/30/2005WO2005058006A2 Methods and compositions comprising bacteriophage nanoparticles
06/30/2005WO2005044989A3 Polynucleotides and polypeptides of anaplasma phagocytophilum and methods of using the same
06/30/2005WO2005042560A3 Non-viral delivery of compounds to mitochondria
06/30/2005WO2005042016A3 Stabilised compositions
06/30/2005WO2005040215A3 Ovomucoid promoters and mehtods of use
06/30/2005WO2005040206A8 Glurp-msp3 fusion protein, immunogenic compositions and malarial vaccines containing it
06/30/2005WO2005037218A3 Lentiviral vector delivery of il-21 for treatment of cancer
06/30/2005WO2005033321A3 Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
06/30/2005WO2005031310A3 Fractal-forming alkylketene dimers for integral membrane protein crystal growth
06/30/2005WO2005026315A3 Method for producing insulin from a natural source and insulin
06/30/2005WO2005024422A3 Methods for identifying inhibitors
06/30/2005WO2005023866A3 Peptides that inhibit complement activation
06/30/2005WO2005021576A3 Methods for for modeling gpcrs and for producing ligand blocking and receptor activating antibodies for same
06/30/2005WO2005021022A3 Stable formulations of peptides
06/30/2005WO2005017093A3 Polypeptides of streptococcus pyogenes
06/30/2005WO2005010174A3 Methods for use of an lkb1/strad7mo25 complex
06/30/2005WO2005009369A3 A ca6 antigen-specific cytotoxic conjugate and methods of using the same
06/30/2005WO2005008251A3 Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
06/30/2005WO2005005466A3 Nucleic and protein sequences from the hxhv virus and uses thereof
06/30/2005WO2005000881A3 Live attenuated viral vaccines for eastern equine encephalitis virus
06/30/2005WO2004111072A3 Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
06/30/2005WO2004103390A3 Stable analogs of peptide and polypeptide therapeutics
06/30/2005WO2004096161A3 Pharmaceutical compositions for treating painful neuropathy and methods of treating same
06/30/2005WO2004093788A3 Desmoglein 4 is a novel gene involved in hair growth
06/30/2005WO2004093566A3 Functional animal muscle protein concentrate composition and process
06/30/2005WO2004092210A3 Molecules having immunomodulatory activity
06/30/2005WO2004055050A3 Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
06/30/2005WO2004035611A3 Peptides binding the phosphatase 2a protein and polynucleotides encoding same
06/30/2005WO2004018999A3 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
06/30/2005WO2004016643A3 Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
06/30/2005WO2004003172A3 Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same
06/30/2005WO2004001381A3 Novel raag10 cell surface target and a family of antibodies recognizing that target
06/30/2005WO2003106479A3 Pokeweed antiviral protein polypeptides with antiviral activity
06/30/2005WO2003097807A3 Cancer-linked gene as target for chemotherapy
06/30/2005WO2003074722A3 Microarrays of cellulose binding chimeric proteins and methods of use thereof
06/30/2005WO2003074001A3 Methods for designing specific inhibitors for pin1 proline isomerase and pin1-related molecules
06/30/2005WO2003066809A3 Mismatch endonucleases and methods of use
06/30/2005WO2003064629A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
06/30/2005WO2003050134A3 Crystalline neutrokine-alpha protein, method of preparation thereof, and method of use thereof
06/30/2005WO2003018611A3 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
06/30/2005US20050144671 Snow1: interacts with Ice1 and regulates CBF expression and freezing tolerance in arabidopsis
06/30/2005US20050144666 Isolated nucleic acid molecule encoding Na+/H+ exchanger polypeptides for extrusion of monovalent cations from the cytosol of cells to provide the cell with increased salt tolerance
06/30/2005US20050144663 Producing transgenic animals for obtaining useful proteins; combining genome from activated donor cell with activated, enucleated oocyte to form nuclear transfer embryo for impregnation
06/30/2005US20050144662 Knockout mouse
06/30/2005US20050144660 Mouse models for studying and treating hepatocellular and gastrointestinal tumors
06/30/2005US20050144659 Animals and cells containing a mutated alpha2delta gene
06/30/2005US20050144658 Test and model for Alzheimer's disease
06/30/2005US20050144133 System and method for processing tokenless biometric electronic transmissions using an electronic rule module clearinghouse
06/30/2005US20050143570 Respiratory chain enzyme genes of coryneform bacteria
06/30/2005US20050143568 Peptide synthesis using filter decanting
06/30/2005US20050143566 exhibits an improved stability at increased pH-values, and accordingly an improved tolerance to cleaning under alkaline conditions; tolerant to one or more cleaning procedures using alkaline agents
06/30/2005US20050143565 Method for separating unmodified hemoglobin from cross-linked hemoglobin
06/30/2005US20050143564 transformed plant cell is obtained by introducing to a plant cell a gene encoding a glycosyltransferase enzyme and a gene encoding an exogenous glycoprotein, cultivating the obtained transformed plant cell
06/30/2005US20050143563 Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
06/30/2005US20050143562 Administering bone polypeptide-1 expressed by a nucleic acid for treating a bone disorder or osteoporosis of a patient
06/30/2005US20050143561 Lawsonia intracellularis proteins, and related methods and materials
06/30/2005US20050143560 Polypeptide analgesics from snail venom; analogous to the naturally available peptides, and which preferably include two disulfide bonds
06/30/2005US20050143559 Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition
06/30/2005US20050143313 Novel peptide, method of production thereof, and pharmaceutical composition containing the same
06/30/2005US20050143312 Compositions and methods for promoting myocardial and peripheral angiogenesis
06/30/2005US20050143311 A peptide fragment containing selenocysteine has a lowered toxicity than selenocystine, exhibits a cytotoxicity-inhibitory activity; screening a drug having cytotoxicity-inhibitory activity by utilizing a cellular sudden death phenomenon in a cell culture system; glutathione peroxidase activity
06/30/2005US20050143309 Alkyl peptide amides and applications
06/30/2005US20050143308 Survivin, a protein that inhibits cellular apoptosis, and its modulation
06/30/2005US20050143307 Biological activity that prevents the binding of formyl methionine-leucine-phenylalanine (fMLP) and/or C5a protein to granulocytes; acute and chronic inflammation reactions and HIV infection
06/30/2005US20050143306 Antigenic peptide fragments of growth differentiation factor 8, and related immunogens, vaccines; Immunization; drug screening
06/30/2005US20050143304 Osteogenic protein/bone morphogenetic proteins of eukaryotic origin
06/30/2005US20050143302 Inhibiting NF-kappa B-dependent target gene expression in a cell; fusions of a NEMO binding domain and a membrane translocation domain (third helix of antennapedia homeodomain or the HIV-1 Tat protein)
06/30/2005US20050143296 Extraction and utilization of cell growth-promoting peptides from silk protein
06/30/2005US20050143294 Neurotrophic factor-3 (NT-3), brain derived neurotrophic factor (BDNF), macrophage growth and differentiation factor (MGDF) and keratinocyte growth factor (KGF); lower isoelectric points; pharmacokinetics; treatment of peripheral neuropathies; bioavailability
06/30/2005US20050143292 Glycopegylated erythropoietin
06/30/2005US20050143291 Contacting a glucose regulated protein (GRP) with an agent( versipelostatin, deoxyadenosine 5.'triphosphate) that regulates the interaction of the GRP with a cytosolic component that mediates apoptosis
06/30/2005US20050143287 Ischemic heart disease, critical limb ischemia, wound healing and burns, cancer, diabetic retinopathy, and inflammatory diseases such as arthritis and psoriasis
06/30/2005US20050143285 Fluorescence based screening assays are provided that allow for the for identification of agents that selectively bind to a ligand-gated ion channels (LGIC); fluorescence resonance energy transfer (FRET)
06/30/2005US20050142657 Expression vector for the production of annexin v
06/30/2005US20050142653 Fermentation for high cell density culture; thrombolytic agents; genetically engineered plasmid carries kanamycin resistant marker
06/30/2005US20050142642 Fc fusion proteins of human erythropoietin with increased biological activities
06/30/2005US20050142641 antigens having altered antigenic profiles, uses in immunotherapy such as allergy vaccination and/or desensitization
06/30/2005US20050142640 MUC-1 derived peptides
06/30/2005US20050142639 Nucleotide sequence with vectors and administering apolipoproteins with data documents for binding lipids and cubulin for treatment of cardiovascular disorders
06/30/2005US20050142637 Long-wavelength FPs
06/30/2005US20050142636 Culturing yeast transformed with albumin-encoding nucleotide sequence in a fermentation medium; gene expression, separation, conditioning, adding sodium octanoate; cationic exchange chromatography, elution, ultrafiltration, sterilization, diafiltration, filling vessel
06/30/2005US20050142634 Novel modulator of non-genomic activity of nuclear receptors (mnar) and uses thereof
06/30/2005US20050142623 a fusion protein containing a reporter protein which can generate a measurable signal and a binding protein which recognizes and binds a target substance; the binding protein is inserted into the amino acid sequence of the reporter protein.